Metronidazole conjugated bismuth sulfide nanoparticles for enhanced X-ray radiation therapy

Javani S., BARSBAY M., Ghaffarlou M., Mousazadeh N., Mohammadi A., Mozafari F., ...Daha Fazla

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, cilt.71, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 71
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.jddst.2022.103336
  • Dergi Adı: JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, EMBASE
  • Anahtar Kelimeler: Hypoxia, Metronidazole, Radiosensitizer, Radiation therapy, Bismuth sulfide, HYPOXIA, RADIOSENSITIZERS, RADIOTHERAPY, NITROIMIDAZOLES, CHEMORADIATION, COMBINATION, GROWTH, TUMORS, OXIDE
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Over the past few years, several types of radiosensitizers have been developed to address the challenges of tumor hypoxia in favor of cancer radiotherapy. In this study, we aimed to synthesize a nano-radiosensitizers via conjugation of metronidazole (Met) to bovine serum albumin coated bismuth sulfide nanoparticles (Bi2S3@BSA NPs), named Bi2S3@BSA-Met. The NPs were characterized with different techniques. Bi2S3@BSA-Met NPs were shown to have a mean hydrodynamic particle size around 154 nm and a spherical shape with homogenous size distribution. Apoptosis assay revealed that the combination of Bi2S3@BSA-Met NPs with X-Ray irradiation potentiated the cell apoptotic rate. Furthermore, one of the most striking results to emerge from the data comparison was the effects of Met on radiosensitization of 4T1 cells under hypoxia condition. Conjugation of Met to Bi2S3@BSA NPs resulted in superior cell cytotoxicity upon X-ray irradiation. Results provide unprecedented evidence for the potential capability of Met as an effective radiation sensitizer for hypoxic tumor cells..